🏷

Classifications

Harrison's Chapter

ICD-O Morphology

◆

Subtypes

4

Classic Kaposi Sarcoma

Indolent form occurring in elderly men of Mediterranean, Eastern European, or Middle Eastern descent. Typically confined to lower extremities with slow progression over years to decades. Not associated with immunosuppression.

Endemic Kaposi Sarcoma

Occurs in sub-Saharan Africa, predating the HIV epidemic. Includes a lymphadenopathic variant affecting children that is rapidly progressive and often fatal. More aggressive than classic form.

Iatrogenic Kaposi Sarcoma

Occurs in organ transplant recipients and others on immunosuppressive therapy. May regress with reduction of immunosuppression. Risk correlates with degree of T-cell immunosuppression.

AIDS-Associated Kaposi Sarcoma

Most common malignancy in AIDS patients, particularly in men who have sex with men. More aggressive with visceral involvement. Incidence has declined dramatically with effective antiretroviral therapy but remains an AIDS-defining illness.

⚙

Pathophysiology

7

HHV-8 Latent Infection of Endothelial Cells

HHV-8 infects endothelial cells and establishes latent infection with expression of latency-associated nuclear antigen (LANA), vFLIP, and vCyclin. LANA maintains the viral episome and inhibits p53 and Rb tumor suppressor function. Latently infected cells undergo spindle cell transformation characteristic of KS.

endothelial cell link

viral transcription link

Downstream

vFLIP-Mediated NF-kappaB Activation Constitutive vFLIP expression activates survival signaling

vCyclin-Mediated Cell Cycle Dysregulation Viral cyclin drives cell cycle progression

vGPCR-Mediated Angiogenic Signaling Lytic gene expression promotes angiogenesis

Show evidence (1 reference)

PMID:7489408 SUPPORT

"KSHV/HHV-8 is present in the flat endothelial cells lining vascular spaces of KS lesions as well as in typical KS spindle cells."

Abstract reports HHV-8 presence in endothelial and spindle cells in KS lesions.

vFLIP-Mediated NF-kappaB Activation

Viral FLICE inhibitory protein (vFLIP) constitutively activates NF-kappaB signaling by interacting with IKK complex. This promotes cell survival, inflammation, and cytokine production. vFLIP also inhibits caspase-8-mediated apoptosis, providing resistance to death receptor-induced cell death.

positive regulation of NF-kappaB transcription factor activity link ↑ INCREASED

Downstream

Apoptosis Resistance and Cell Survival NF-kappaB activates anti-apoptotic genes

vCyclin-Mediated Cell Cycle Dysregulation

Viral cyclin (vCyclin) forms active complexes with CDK6 that are resistant to inhibition by p16INK4A, p21, and p27. This drives cells through G1/S checkpoint regardless of normal growth regulatory signals, contributing to uncontrolled proliferation.

G1/S transition of mitotic cell cycle link ⚠ ABNORMAL

Downstream

Uncontrolled Cell Proliferation Cell cycle checkpoint bypass leads to proliferation

vGPCR-Mediated Angiogenic Signaling

The viral G protein-coupled receptor (vGPCR) is expressed during lytic reactivation and activates multiple signaling pathways in a ligand-independent manner, including VEGF production and MAPK activation. vGPCR is highly oncogenic and promotes the angiogenic, inflammatory microenvironment characteristic of KS lesions.

signal transduction link ↑ INCREASED

Downstream

Angiogenic Proliferation VEGF and inflammatory cytokines drive vascular proliferation

Apoptosis Resistance and Cell Survival

Multiple viral genes cooperate to prevent apoptosis: vFLIP inhibits caspase-8 and activates NF-kappaB; LANA inhibits p53; vBCL-2 mimics cellular BCL-2. This multi-layered apoptosis resistance enables survival and accumulation of infected cells.

apoptotic process link ↓ DECREASED

Uncontrolled Cell Proliferation

Combined effects of vCyclin, LANA-mediated Rb inhibition, and growth factor signaling drive spindle cell proliferation, forming the characteristic KS lesions.

cell population proliferation link ↑ INCREASED

Angiogenic Proliferation

KS lesions are highly vascular due to vGPCR-induced VEGF and inflammatory cytokine production. The aberrant angiogenesis creates the characteristic red-purple appearance and contributes to edema and hemorrhage.

endothelial cell link

angiogenesis link ↑ INCREASED

Show evidence (1 reference)

PMID:16188485 SUPPORT Human Clinical

"the proliferation of spindle cells (considered as the Kaposi's sarcoma tumor cells) associated with inflammation and neo-angiogenesis"

Histopathology review confirms spindle cell proliferation is intrinsically associated with neo-angiogenesis in KS lesions, supporting the angiogenic phenotype as a defining feature of the tumor.

✶

Histopathology

1

Spindle Cell Vascular Tumor VERY_FREQUENT

Spindle cells represent the main cell type in Kaposi sarcoma lesions.

Show evidence (1 reference)

PMID:16188485 SUPPORT

"Spindle cells represent the main cell type of the advanced final nodular stage"

Abstract notes spindle cells as the main cell type in advanced Kaposi sarcoma lesions.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

5

Cardiovascular 1

Lymphadenopathy FREQUENT Lymphadenopathy (HP:0002716)

Show evidence (1 reference)

PMID:3029191 SUPPORT Human Clinical

"The most common sites for visceral involvement with Kaposi's sarcoma were as follows: lung (37%), gastrointestinal tract (50%), and lymph nodes (50%)."

Postmortem series of 24 AIDS patients with Kaposi sarcoma found lymph node involvement in 50% of cases, supporting lymphadenopathy as a frequent phenotype in advanced AIDS-associated disease.

Digestive 1

GI Involvement FREQUENT Abnormality of the gastrointestinal tract (HP:0011024)

Show evidence (1 reference)

PMID:1947766 SUPPORT Human Clinical

"Gastrointestinal lesions were found in 17 cases (51%): 5 patients (15%) had both upper and lower GI tract involvement, 8 patients (24%) had only gastroduodenal lesions, and 4 (12%) only lower tract disease."

Prospective study of 33 AIDS patients with Kaposi sarcoma identified gastrointestinal lesions in 51% of cases (FREQUENT per HPO frequency bins), with 80% clinically silent.

Integument 1

Cutaneous Lesions VERY_FREQUENT Localized skin lesion (HP:0011355)

Show evidence (1 reference)

PMID:30205412 SUPPORT Human Clinical

"Cutaneous lesions occurred more often (81.6%), mainly located on the lower limbs (47.7%); mucous lesions were found in 15.8% of the patients, while 8 patients (3.0%) had associated visceral lesions."

Retrospective cross-sectional study of 266 HIV-infected Kaposi sarcoma patients in Cameroon documents cutaneous lesions in 81.6% of cases, predominantly on the lower limbs, supporting classification of cutaneous lesions as a very frequent and diagnostic phenotype.

Metabolism 1

Lymphedema OCCASIONAL Lymphedema (HP:0001004)

Show evidence (1 reference)

PMID:30205412 SUPPORT Human Clinical

"The lesions predominantly were lymphedemas (28.6%) and papulonodules (21.1%)."

Same Cameroon HIV-Kaposi sarcoma cohort identifies lymphedema-type lesions in 28.6% of cases, which falls in the HPO OCCASIONAL frequency range (5-29%).

Other 1

Pulmonary Involvement FREQUENT Abnormal lung morphology (HP:0002088)

Show evidence (1 reference)

PMID:3029191 SUPPORT Human Clinical

"The most common sites for visceral involvement with Kaposi's sarcoma were as follows: lung (37%), gastrointestinal tract (50%), and lymph nodes (50%)."

Postmortem series of 24 AIDS patients with Kaposi sarcoma identified pulmonary involvement in 37% of cases (FREQUENT per HPO frequency bins), a clinically important finding associated with poor prognosis.

🧬

Genetic Associations

1

HHV-8 Viral Oncogenes (Viral Oncogene Expression)

💊

Treatments

4

Antiretroviral Therapy

Action: pharmacotherapy MAXO:0000058

For AIDS-associated KS, initiation or optimization of antiretroviral therapy (ART) is the most important intervention. Immune reconstitution leads to regression in many cases without KS-specific treatment.

Chemotherapy

Action: chemotherapy MAXO:0000647

Agent: doxorubicin ↗ paclitaxel ↗

For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.

Local Therapy

Action: radiation therapy MAXO:0000014

Localized lesions may be treated with radiation, intralesional chemotherapy, cryotherapy, or surgical excision for palliation or cosmesis.

Reduction of Immunosuppression

Action: pharmacotherapy MAXO:0000058

For iatrogenic KS in transplant recipients, reduction or modification of immunosuppressive therapy may lead to regression. Switching to sirolimus (mTOR inhibitor) may have anti-tumor effects in addition to immunosuppression.

🔬

Biochemical Markers

2

HHV-8 Viral Load

LANA Immunohistochemistry

{ }

Source YAML

click to show

name: Kaposi Sarcoma
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-09T17:39:56Z'
description: >-
  Kaposi sarcoma (KS) is a vascular neoplasm caused by Human Herpesvirus 8 (HHV-8),
  also known as Kaposi sarcoma-associated herpesvirus (KSHV). The tumor arises from
  infected endothelial cells that acquire a spindle cell morphology. Four clinical
  variants exist: classic (Mediterranean), endemic (African), iatrogenic (transplant-
  associated), and epidemic (AIDS-associated). HHV-8 viral oncoproteins including
  vGPCR, vFLIP, vCyclin, and LANA drive oncogenesis through activation of NF-kappaB,
  PI3K-AKT, and MAPK signaling pathways. The disease is characterized by multifocal
  red-purple vascular lesions of skin and viscera.
categories:
- Soft Tissue Sarcoma
- Virus-Associated Cancer
- Vascular Tumor
parents:
- sarcoma
has_subtypes:
- name: Classic Kaposi Sarcoma
  description: >-
    Indolent form occurring in elderly men of Mediterranean, Eastern European,
    or Middle Eastern descent. Typically confined to lower extremities with
    slow progression over years to decades. Not associated with immunosuppression.
- name: Endemic Kaposi Sarcoma
  description: >-
    Occurs in sub-Saharan Africa, predating the HIV epidemic. Includes a
    lymphadenopathic variant affecting children that is rapidly progressive
    and often fatal. More aggressive than classic form.
- name: Iatrogenic Kaposi Sarcoma
  description: >-
    Occurs in organ transplant recipients and others on immunosuppressive
    therapy. May regress with reduction of immunosuppression. Risk correlates
    with degree of T-cell immunosuppression.
- name: AIDS-Associated Kaposi Sarcoma
  description: >-
    Most common malignancy in AIDS patients, particularly in men who have
    sex with men. More aggressive with visceral involvement. Incidence has
    declined dramatically with effective antiretroviral therapy but remains
    an AIDS-defining illness.
infectious_agent:
- name: Human Herpesvirus 8 (HHV-8/KSHV)
  infectious_agent_term:
    preferred_term: Human gammaherpesvirus 8
    term:
      id: NCBITaxon:37296
      label: Human gammaherpesvirus 8
  description: >-
    HHV-8 (KSHV) is the causative agent of all forms of Kaposi sarcoma. The virus
    encodes multiple oncoproteins that drive transformation: vGPCR (viral G protein-
    coupled receptor) activates angiogenic signaling; vFLIP activates NF-kappaB
    for cell survival; vCyclin drives cell cycle progression; LANA maintains viral
    latency and inhibits p53 and Rb tumor suppressors. The virus establishes latent
    infection in endothelial cells, with lytic reactivation contributing to
    paracrine signaling and tumor progression.
  evidence:
  - reference: PMID:34731971
    reference_title: "[Human herpes virus 8: molecules determinants of oncogenesis and modulation of the immune response]."
    supports: SUPPORT
    snippet: "HHV8 is the etiological agent of Kaposi sarcoma, and of rare B cell lymphoproliferative disorders mostly observed in immunocompromised hosts (patients with AIDS, transplant organ recipients) such as primary effusion lymphoma and the plasma cell variant of multicentric Castleman disease."
    explanation: "Confirms HHV-8/KSHV as the etiologic agent of Kaposi sarcoma."
pathophysiology:
- name: HHV-8 Latent Infection of Endothelial Cells
  description: >-
    HHV-8 infects endothelial cells and establishes latent infection with expression
    of latency-associated nuclear antigen (LANA), vFLIP, and vCyclin. LANA maintains
    the viral episome and inhibits p53 and Rb tumor suppressor function. Latently
    infected cells undergo spindle cell transformation characteristic of KS.
  evidence:
  - reference: PMID:7489408
    reference_title: "Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells."
    supports: SUPPORT
    snippet: "KSHV/HHV-8 is present in the flat endothelial cells lining vascular spaces of KS lesions as well as in typical KS spindle cells."
    explanation: "Abstract reports HHV-8 presence in endothelial and spindle cells in KS lesions."
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: viral transcription
    term:
      id: GO:0019083
      label: viral transcription
  downstream:
  - target: vFLIP-Mediated NF-kappaB Activation
    description: Constitutive vFLIP expression activates survival signaling
  - target: vCyclin-Mediated Cell Cycle Dysregulation
    description: Viral cyclin drives cell cycle progression
  - target: vGPCR-Mediated Angiogenic Signaling
    description: Lytic gene expression promotes angiogenesis
- name: vFLIP-Mediated NF-kappaB Activation
  description: >-
    Viral FLICE inhibitory protein (vFLIP) constitutively activates NF-kappaB
    signaling by interacting with IKK complex. This promotes cell survival,
    inflammation, and cytokine production. vFLIP also inhibits caspase-8-mediated
    apoptosis, providing resistance to death receptor-induced cell death.
  biological_processes:
  - preferred_term: positive regulation of NF-kappaB transcription factor activity
    modifier: INCREASED
    term:
      id: GO:0043123
      label: positive regulation of canonical NF-kappaB signal transduction
  downstream:
  - target: Apoptosis Resistance and Cell Survival
    description: NF-kappaB activates anti-apoptotic genes
- name: vCyclin-Mediated Cell Cycle Dysregulation
  description: >-
    Viral cyclin (vCyclin) forms active complexes with CDK6 that are resistant
    to inhibition by p16INK4A, p21, and p27. This drives cells through G1/S
    checkpoint regardless of normal growth regulatory signals, contributing
    to uncontrolled proliferation.
  biological_processes:
  - preferred_term: G1/S transition of mitotic cell cycle
    modifier: ABNORMAL
    term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
  downstream:
  - target: Uncontrolled Cell Proliferation
    description: Cell cycle checkpoint bypass leads to proliferation
- name: vGPCR-Mediated Angiogenic Signaling
  description: >-
    The viral G protein-coupled receptor (vGPCR) is expressed during lytic
    reactivation and activates multiple signaling pathways in a ligand-independent
    manner, including VEGF production and MAPK activation. vGPCR is highly
    oncogenic and promotes the angiogenic, inflammatory microenvironment
    characteristic of KS lesions.
  biological_processes:
  - preferred_term: signal transduction
    modifier: INCREASED
    term:
      id: GO:0007165
      label: signal transduction
  downstream:
  - target: Angiogenic Proliferation
    description: VEGF and inflammatory cytokines drive vascular proliferation
- name: Apoptosis Resistance and Cell Survival
  description: >-
    Multiple viral genes cooperate to prevent apoptosis: vFLIP inhibits
    caspase-8 and activates NF-kappaB; LANA inhibits p53; vBCL-2 mimics
    cellular BCL-2. This multi-layered apoptosis resistance enables survival
    and accumulation of infected cells.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
- name: Uncontrolled Cell Proliferation
  description: >-
    Combined effects of vCyclin, LANA-mediated Rb inhibition, and growth
    factor signaling drive spindle cell proliferation, forming the
    characteristic KS lesions.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
- name: Angiogenic Proliferation
  description: >-
    KS lesions are highly vascular due to vGPCR-induced VEGF and inflammatory
    cytokine production. The aberrant angiogenesis creates the characteristic
    red-purple appearance and contributes to edema and hemorrhage.
  evidence:
  - reference: PMID:16188485
    reference_title: "Spindle cells and their role in Kaposi's sarcoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the proliferation of spindle cells (considered as the Kaposi's sarcoma tumor cells) associated with inflammation and neo-angiogenesis"
    explanation: Histopathology review confirms spindle cell proliferation is intrinsically associated with neo-angiogenesis in KS lesions, supporting the angiogenic phenotype as a defining feature of the tumor.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
histopathology:
- name: Spindle Cell Vascular Tumor
  finding_term:
    preferred_term: Spindle Cell Pattern
    term:
      id: NCIT:C53643
      label: Spindle Cell Pattern
  frequency: VERY_FREQUENT
  description: Spindle cells represent the main cell type in Kaposi sarcoma lesions.
  evidence:
  - reference: PMID:16188485
    reference_title: "Spindle cells and their role in Kaposi's sarcoma."
    supports: SUPPORT
    snippet: "Spindle cells represent the main cell type of the advanced final nodular stage"
    explanation: Abstract notes spindle cells as the main cell type in advanced Kaposi sarcoma lesions.

phenotypes:
- category: Dermatologic
  name: Cutaneous Lesions
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Characteristic red-purple to brown-black macules, papules, plaques, or
    nodules on the skin. Lesions are typically multifocal and may occur
    anywhere but favor the lower extremities, face (especially nose), and
    oral mucosa in AIDS-associated KS.
  phenotype_term:
    preferred_term: Localized skin lesion
    term:
      id: HP:0011355
      label: Localized skin lesion
  evidence:
  - reference: PMID:30205412
    reference_title: "Epidemiological and Clinical Patterns of Kaposi Sarcoma: A 16-Year Retrospective Cross-Sectional Study from Yaoundé, Cameroon."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cutaneous lesions occurred more often (81.6%), mainly located on the lower limbs (47.7%); mucous lesions were found in 15.8% of the patients, while 8 patients (3.0%) had associated visceral lesions."
    explanation: >-
      Retrospective cross-sectional study of 266 HIV-infected Kaposi
      sarcoma patients in Cameroon documents cutaneous lesions in
      81.6% of cases, predominantly on the lower limbs, supporting
      classification of cutaneous lesions as a very frequent and
      diagnostic phenotype.
- category: Dermatologic
  name: Lymphedema
  frequency: OCCASIONAL
  description: >-
    Localized or diffuse lymphedema, particularly of the lower extremities,
    face, or genitalia. Results from lymphatic obstruction by tumor and
    inflammatory processes.
  phenotype_term:
    preferred_term: Lymphedema
    term:
      id: HP:0001004
      label: Lymphedema
  evidence:
  - reference: PMID:30205412
    reference_title: "Epidemiological and Clinical Patterns of Kaposi Sarcoma: A 16-Year Retrospective Cross-Sectional Study from Yaoundé, Cameroon."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The lesions predominantly were lymphedemas (28.6%) and papulonodules (21.1%)."
    explanation: >-
      Same Cameroon HIV-Kaposi sarcoma cohort identifies lymphedema-type
      lesions in 28.6% of cases, which falls in the HPO OCCASIONAL
      frequency range (5-29%).
- category: Lymphatic
  name: Lymphadenopathy
  frequency: FREQUENT
  description: >-
    Lymph node involvement may occur, especially in endemic African variant
    (lymphadenopathic KS) and advanced AIDS-associated disease.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:3029191
    reference_title: "Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common sites for visceral involvement with Kaposi's sarcoma were as follows: lung (37%), gastrointestinal tract (50%), and lymph nodes (50%)."
    explanation: >-
      Postmortem series of 24 AIDS patients with Kaposi sarcoma found
      lymph node involvement in 50% of cases, supporting lymphadenopathy
      as a frequent phenotype in advanced AIDS-associated disease.
- category: Gastrointestinal
  name: GI Involvement
  frequency: FREQUENT
  description: >-
    Visceral involvement of the gastrointestinal tract may cause bleeding,
    obstruction, or protein-losing enteropathy. Often asymptomatic and
    discovered on endoscopy.
  phenotype_term:
    preferred_term: Abnormality of the gastrointestinal tract
    term:
      id: HP:0011024
      label: Abnormality of the gastrointestinal tract
  evidence:
  - reference: PMID:1947766
    reference_title: "Kaposi's sarcoma and AIDS: frequency of gastrointestinal involvement and its effect on survival. A prospective study in a heterogeneous population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gastrointestinal lesions were found in 17 cases (51%): 5 patients (15%) had both upper and lower GI tract involvement, 8 patients (24%) had only gastroduodenal lesions, and 4 (12%) only lower tract disease."
    explanation: >-
      Prospective study of 33 AIDS patients with Kaposi sarcoma
      identified gastrointestinal lesions in 51% of cases (FREQUENT
      per HPO frequency bins), with 80% clinically silent.
- category: Pulmonary
  name: Pulmonary Involvement
  frequency: FREQUENT
  description: >-
    Anatomical lung involvement by Kaposi sarcoma lesions, with diffuse
    infiltrates or nodules on chest imaging and angioproliferative
    tumor deposits at autopsy. Associated with poor prognosis.
  phenotype_term:
    preferred_term: Abnormal lung morphology
    term:
      id: HP:0002088
      label: Abnormal lung morphology
  evidence:
  - reference: PMID:3029191
    reference_title: "Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common sites for visceral involvement with Kaposi's sarcoma were as follows: lung (37%), gastrointestinal tract (50%), and lymph nodes (50%)."
    explanation: >-
      Postmortem series of 24 AIDS patients with Kaposi sarcoma
      identified pulmonary involvement in 37% of cases (FREQUENT per
      HPO frequency bins), a clinically important finding associated
      with poor prognosis.
biochemical:
- name: HHV-8 Viral Load
  notes: >-
    HHV-8 DNA quantification by PCR correlates with disease activity.
    Rising viral loads may indicate disease progression or lytic reactivation.
- name: LANA Immunohistochemistry
  notes: >-
    Detection of latency-associated nuclear antigen (LANA) in tumor cells
    by immunohistochemistry is the gold standard for confirming HHV-8
    infection and diagnosing Kaposi sarcoma.
genetic:
- name: HHV-8 Viral Oncogenes
  association: Viral Oncogene Expression
  notes: >-
    HHV-8 encodes multiple oncogenes: vGPCR (constitutively active GPCR),
    vFLIP (NF-kappaB activator), vCyclin (cell cycle driver), LANA (tumor
    suppressor inhibitor), vIL-6, vBCL-2, and K1. These cooperate to drive
    transformation through multiple mechanisms.
treatments:
- name: Antiretroviral Therapy
  description: >-
    For AIDS-associated KS, initiation or optimization of antiretroviral
    therapy (ART) is the most important intervention. Immune reconstitution
    leads to regression in many cases without KS-specific treatment.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Chemotherapy
  description: >-
    For advanced or rapidly progressive disease, liposomal doxorubicin
    or paclitaxel are first-line systemic chemotherapies. Reserved for
    patients with visceral involvement or disease not controlled by ART.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: doxorubicin
      term:
        id: CHEBI:28748
        label: doxorubicin
    - preferred_term: paclitaxel
      term:
        id: CHEBI:45863
        label: paclitaxel
- name: Local Therapy
  description: >-
    Localized lesions may be treated with radiation, intralesional
    chemotherapy, cryotherapy, or surgical excision for palliation
    or cosmesis.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
- name: Reduction of Immunosuppression
  description: >-
    For iatrogenic KS in transplant recipients, reduction or modification
    of immunosuppressive therapy may lead to regression. Switching to
    sirolimus (mTOR inhibitor) may have anti-tumor effects in addition
    to immunosuppression.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
disease_term:
  preferred_term: Kaposi sarcoma
  term:
    id: MONDO:0005055
    label: Kaposi's sarcoma

classifications:
  icdo_morphology:
    classification_value: Sarcoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
references:
- reference: DOI:10.1080/14787210.2023.2247161
  title: 'Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: 'Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies'
    supporting_text: 'Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies'
- reference: DOI:10.1101/2024.09.27.615429
  title: Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of Kaposi sarcoma in patient-derived mouse models
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: Kaposi sarcoma (KS) is defined by aberrant angiogenesis driven by Kaposi sarcoma herpesvirus (KSHV)-infected spindle cells with endothelial characteristics.
    supporting_text: Kaposi sarcoma (KS) is defined by aberrant angiogenesis driven by Kaposi sarcoma herpesvirus (KSHV)-infected spindle cells with endothelial characteristics.
    evidence:
    - reference: DOI:10.1101/2024.09.27.615429
      reference_title: Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of Kaposi sarcoma in patient-derived mouse models
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Kaposi sarcoma (KS) is defined by aberrant angiogenesis driven by Kaposi sarcoma herpesvirus (KSHV)-infected spindle cells with endothelial characteristics.
      explanation: Deep research cited this publication as relevant literature for Kaposi Sarcoma.
- reference: DOI:10.1158/2767-9764.crc-24-0102
  title: 'Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: Kaposi sarcoma is a rare angioproliferative disease associated with human herpes virus-8 (HHV-8) infection.
    supporting_text: Kaposi sarcoma is a rare angioproliferative disease associated with human herpes virus-8 (HHV-8) infection.
    evidence:
    - reference: DOI:10.1158/2767-9764.crc-24-0102
      reference_title: 'Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Kaposi sarcoma is a rare angioproliferative disease associated with human herpes virus-8 (HHV-8) infection.
      explanation: Deep research cited this publication as relevant literature for Kaposi Sarcoma.
- reference: DOI:10.1186/s12885-023-11402-3
  title: 'Incident Kaposi sarcoma during the expansion of antiretroviral therapy eligibility in Nigeria: a retrospective cohort study'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: The expansion of antiretroviral therapy (ART) eligibility could lead to earlier initiation of Human Immunodeficiency Virus (HIV) treatment and consequently reduce the risk of HIV-associated Kaposi Sarcoma (KS).
    supporting_text: The expansion of antiretroviral therapy (ART) eligibility could lead to earlier initiation of Human Immunodeficiency Virus (HIV) treatment and consequently reduce the risk of HIV-associated Kaposi Sarcoma (KS).
    evidence:
    - reference: DOI:10.1186/s12885-023-11402-3
      reference_title: 'Incident Kaposi sarcoma during the expansion of antiretroviral therapy eligibility in Nigeria: a retrospective cohort study'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The expansion of antiretroviral therapy (ART) eligibility could lead to earlier initiation of Human Immunodeficiency Virus (HIV) treatment and consequently reduce the risk of HIV-associated Kaposi Sarcoma (KS).
      explanation: Deep research cited this publication as relevant literature for Kaposi Sarcoma.
- reference: DOI:10.1186/s13027-025-00710-x
  title: Kaposi sarcoma incidence and mortality trends and disparities in the United States
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: Kaposi sarcoma (KS) is an angioproliferative tumor caused by human herpesvirus 8 and is an AIDS-defining illness.
    supporting_text: Kaposi sarcoma (KS) is an angioproliferative tumor caused by human herpesvirus 8 and is an AIDS-defining illness.
    evidence:
    - reference: DOI:10.1186/s13027-025-00710-x
      reference_title: Kaposi sarcoma incidence and mortality trends and disparities in the United States
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Kaposi sarcoma (KS) is an angioproliferative tumor caused by human herpesvirus 8 and is an AIDS-defining illness.
      explanation: Deep research cited this publication as relevant literature for Kaposi Sarcoma.
- reference: DOI:10.1371/journal.pone.0280209
  title: 'Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: 'Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial'
    supporting_text: High HHV-8 viral load (VL) in Kaposi Sarcoma (KS) has been associated with Severe Immune Reconstitution Inflammatory Syndrome (Severe-IRIS-KS), which can occur after initiating cART, and leads to high mortality, particularly in patients with pulmonary involvement.
    evidence:
    - reference: DOI:10.1371/journal.pone.0280209
      reference_title: 'Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: High HHV-8 viral load (VL) in Kaposi Sarcoma (KS) has been associated with Severe Immune Reconstitution Inflammatory Syndrome (Severe-IRIS-KS), which can occur after initiating cART, and leads to high mortality, particularly in patients with pulmonary involvement.
      explanation: Deep research cited this publication as relevant literature for Kaposi Sarcoma.
- reference: DOI:10.2147/ott.s468787
  title: 'Management and Future Therapeutic Perspectives of Classic Kaposi’s Sarcoma: An Evidence-Based Review'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: 'Management and Future Therapeutic Perspectives of Classic Kaposi’s Sarcoma: An Evidence-Based Review'
    supporting_text: 'Management and Future Therapeutic Perspectives of Classic Kaposi’s Sarcoma: An Evidence-Based Review'
- reference: DOI:10.3390/cancers16040691
  title: 'Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms.
    supporting_text: Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms.
    evidence:
    - reference: DOI:10.3390/cancers16040691
      reference_title: 'Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms.
      explanation: Deep research cited this publication as relevant literature for Kaposi Sarcoma.
- reference: DOI:10.3390/cancers18061008
  title: 'Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: Classic Kaposi sarcoma (CKS) is a rare vascular neoplasm driven by infection with Kaposi sarcoma-associated herpesvirus (KSHV) and characterized by a heterogeneous geographic distribution.
    supporting_text: Classic Kaposi sarcoma (CKS) is a rare vascular neoplasm driven by infection with Kaposi sarcoma-associated herpesvirus (KSHV) and characterized by a heterogeneous geographic distribution.
    evidence:
    - reference: DOI:10.3390/cancers18061008
      reference_title: 'Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Classic Kaposi sarcoma (CKS) is a rare vascular neoplasm driven by infection with Kaposi sarcoma-associated herpesvirus (KSHV) and characterized by a heterogeneous geographic distribution.
      explanation: Deep research cited this publication as relevant literature for Kaposi Sarcoma.
- reference: DOI:10.3390/ijms262010058
  title: 'Recent Advances in the Histopathology, Molecular Biology, and Treatment of Kaposi Sarcoma: A Contemporary Review'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: Kaposi sarcoma (KS) is an intermediate-grade vascular tumour that has undergone major treatment and diagnostic breakthroughs following the discovery of Human herpesvirus 8 (HHV8).
    supporting_text: Kaposi sarcoma (KS) is an intermediate-grade vascular tumour that has undergone major treatment and diagnostic breakthroughs following the discovery of Human herpesvirus 8 (HHV8).
    evidence:
    - reference: DOI:10.3390/ijms262010058
      reference_title: 'Recent Advances in the Histopathology, Molecular Biology, and Treatment of Kaposi Sarcoma: A Contemporary Review'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Kaposi sarcoma (KS) is an intermediate-grade vascular tumour that has undergone major treatment and diagnostic breakthroughs following the discovery of Human herpesvirus 8 (HHV8).
      explanation: Deep research cited this publication as relevant literature for Kaposi Sarcoma.
- reference: DOI:10.7759/cureus.52527
  title: 'Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis'
  found_in:
  - Kaposi_Sarcoma-deep-research-falcon.md
  findings:
  - statement: 'Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis'
    supporting_text: 'Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis'

📚

References & Deep Research

References

11

DOI:10.1080/14787210.2023.2247161

Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies

1 finding

Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies

"Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies"

DOI:10.1101/2024.09.27.615429

Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of Kaposi sarcoma in patient-derived mouse models

1 finding

Kaposi sarcoma (KS) is defined by aberrant angiogenesis driven by Kaposi sarcoma herpesvirus (KSHV)-infected spindle cells with endothelial characteristics.

"Kaposi sarcoma (KS) is defined by aberrant angiogenesis driven by Kaposi sarcoma herpesvirus (KSHV)-infected spindle cells with endothelial characteristics."

Show evidence (1 reference)

DOI:10.1101/2024.09.27.615429 SUPPORT Model Organism

"Kaposi sarcoma (KS) is defined by aberrant angiogenesis driven by Kaposi sarcoma herpesvirus (KSHV)-infected spindle cells with endothelial characteristics."

Deep research cited this publication as relevant literature for Kaposi Sarcoma.

DOI:10.1158/2767-9764.crc-24-0102

Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly

1 finding

Kaposi sarcoma is a rare angioproliferative disease associated with human herpes virus-8 (HHV-8) infection.

"Kaposi sarcoma is a rare angioproliferative disease associated with human herpes virus-8 (HHV-8) infection."

Show evidence (1 reference)

DOI:10.1158/2767-9764.crc-24-0102 SUPPORT Human Clinical

"Kaposi sarcoma is a rare angioproliferative disease associated with human herpes virus-8 (HHV-8) infection."

Deep research cited this publication as relevant literature for Kaposi Sarcoma.

DOI:10.1186/s12885-023-11402-3

Incident Kaposi sarcoma during the expansion of antiretroviral therapy eligibility in Nigeria: a retrospective cohort study

1 finding

The expansion of antiretroviral therapy (ART) eligibility could lead to earlier initiation of Human Immunodeficiency Virus (HIV) treatment and consequently reduce the risk of HIV-associated Kaposi Sarcoma (KS).

"The expansion of antiretroviral therapy (ART) eligibility could lead to earlier initiation of Human Immunodeficiency Virus (HIV) treatment and consequently reduce the risk of HIV-associated Kaposi Sarcoma (KS)."

Show evidence (1 reference)

DOI:10.1186/s12885-023-11402-3 SUPPORT Human Clinical

"The expansion of antiretroviral therapy (ART) eligibility could lead to earlier initiation of Human Immunodeficiency Virus (HIV) treatment and consequently reduce the risk of HIV-associated Kaposi Sarcoma (KS)."

Deep research cited this publication as relevant literature for Kaposi Sarcoma.

DOI:10.1186/s13027-025-00710-x

Kaposi sarcoma incidence and mortality trends and disparities in the United States

1 finding

Kaposi sarcoma (KS) is an angioproliferative tumor caused by human herpesvirus 8 and is an AIDS-defining illness.

"Kaposi sarcoma (KS) is an angioproliferative tumor caused by human herpesvirus 8 and is an AIDS-defining illness."

Show evidence (1 reference)

DOI:10.1186/s13027-025-00710-x SUPPORT Human Clinical

"Kaposi sarcoma (KS) is an angioproliferative tumor caused by human herpesvirus 8 and is an AIDS-defining illness."

Deep research cited this publication as relevant literature for Kaposi Sarcoma.

DOI:10.1371/journal.pone.0280209

Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial

1 finding

Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial

"High HHV-8 viral load (VL) in Kaposi Sarcoma (KS) has been associated with Severe Immune Reconstitution Inflammatory Syndrome (Severe-IRIS-KS), which can occur after initiating cART, and leads to high mortality, particularly in patients with pulmonary involvement."

Show evidence (1 reference)

DOI:10.1371/journal.pone.0280209 SUPPORT Human Clinical

"High HHV-8 viral load (VL) in Kaposi Sarcoma (KS) has been associated with Severe Immune Reconstitution Inflammatory Syndrome (Severe-IRIS-KS), which can occur after initiating cART, and leads to high mortality, particularly in patients with pulmonary involvement."

Deep research cited this publication as relevant literature for Kaposi Sarcoma.

DOI:10.2147/ott.s468787

Management and Future Therapeutic Perspectives of Classic Kaposi’s Sarcoma: An Evidence-Based Review

1 finding

Management and Future Therapeutic Perspectives of Classic Kaposi’s Sarcoma: An Evidence-Based Review

"Management and Future Therapeutic Perspectives of Classic Kaposi’s Sarcoma: An Evidence-Based Review"

DOI:10.3390/cancers16040691

Kaposi’s Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series

1 finding

Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms.

"Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms."

Show evidence (1 reference)

DOI:10.3390/cancers16040691 SUPPORT Human Clinical

"Kaposi’s sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms."

Deep research cited this publication as relevant literature for Kaposi Sarcoma.

DOI:10.3390/cancers18061008

Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches

1 finding

Classic Kaposi sarcoma (CKS) is a rare vascular neoplasm driven by infection with Kaposi sarcoma-associated herpesvirus (KSHV) and characterized by a heterogeneous geographic distribution.

"Classic Kaposi sarcoma (CKS) is a rare vascular neoplasm driven by infection with Kaposi sarcoma-associated herpesvirus (KSHV) and characterized by a heterogeneous geographic distribution."

Show evidence (1 reference)

DOI:10.3390/cancers18061008 SUPPORT Human Clinical

"Classic Kaposi sarcoma (CKS) is a rare vascular neoplasm driven by infection with Kaposi sarcoma-associated herpesvirus (KSHV) and characterized by a heterogeneous geographic distribution."

Deep research cited this publication as relevant literature for Kaposi Sarcoma.

DOI:10.3390/ijms262010058

Recent Advances in the Histopathology, Molecular Biology, and Treatment of Kaposi Sarcoma: A Contemporary Review

1 finding

Kaposi sarcoma (KS) is an intermediate-grade vascular tumour that has undergone major treatment and diagnostic breakthroughs following the discovery of Human herpesvirus 8 (HHV8).

"Kaposi sarcoma (KS) is an intermediate-grade vascular tumour that has undergone major treatment and diagnostic breakthroughs following the discovery of Human herpesvirus 8 (HHV8)."

Show evidence (1 reference)

DOI:10.3390/ijms262010058 SUPPORT Human Clinical

"Kaposi sarcoma (KS) is an intermediate-grade vascular tumour that has undergone major treatment and diagnostic breakthroughs following the discovery of Human herpesvirus 8 (HHV8)."

Deep research cited this publication as relevant literature for Kaposi Sarcoma.

DOI:10.7759/cureus.52527

Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis

1 finding

Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis

"Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis"

Deep Research

1

Falcon ▸

Kaposi Sarcoma (KS): Disease Characteristics Research Report

Edison Scientific Literature 25 citations 2026-05-09T09:50:32.891969

Kaposi Sarcoma (KS): Disease Characteristics Research Report

Target Disease

Disease name: Kaposi sarcoma (KS)
Category: Vascular (angioproliferative) tumor/neoplasm of endothelial lineage, strongly associated with an oncogenic herpesvirus (KSHV/HHV-8), typically requiring immune dysfunction/immunosuppression as a cofactor (russo2024kaposi’ssarcomaevaluation pages 1-2, denaro2024managementandfuture pages 1-2).
Key identifiers (available in retrieved sources):
ICD-10: C46 (Kaposi sarcoma) and B21.0 (HIV disease resulting in Kaposi’s sarcoma) are used for surveillance in CDC WONDER analyses (raja2025kaposisarcomaincidence pages 1-2).
Open Targets / EFO: EFO_0000558 (Kaposi’s sarcoma) and EFO_0002613 (iatrogenic Kaposi’s sarcoma) appear in Open Targets disease entities (OpenTargets Search: Kaposi sarcoma).
MONDO (available from Open Targets as susceptibility entity): MONDO_0007845 (“Kaposi sarcoma, susceptibility to”) (OpenTargets Search: Kaposi sarcoma).
Note on missing IDs: This tool run did not retrieve a MONDO identifier explicitly for KS itself (distinct from the “susceptibility to” concept), nor MeSH/Orphanet/OMIM IDs; these would normally be retrieved from ontology portals (e.g., MONDO, MeSH Browser, Orphanet) but were not available within the current evidence set.

Synonyms / alternative names

“Kaposi’s sarcoma” (with apostrophe), “KS” (russo2024kaposi’ssarcomaevaluation pages 1-2, patel2023clinicalmanagementof pages 2-4).
Subtype descriptors commonly used: classic KS, endemic (African) KS, iatrogenic/post-transplant KS, epidemic/HIV-associated KS; some reviews describe a proposed HIV-negative MSM-associated subtype (denaro2024managementandfuture pages 1-2, patel2023clinicalmanagementof pages 2-4).

Evidence provenance

This report is derived from aggregated disease-level resources (peer-reviewed reviews and epidemiologic studies) plus cohort studies/trials, not from individual EHRs (russo2024kaposi’ssarcomaevaluation pages 1-2, patel2023clinicalmanagementof pages 2-4, raja2025kaposisarcomaincidence pages 1-2, volkow2023impactofvalganciclovir pages 1-2, akanbi2023incidentkaposisarcoma pages 2-4).

1. Disease Information (overview and current understanding)

Kaposi sarcoma is a vascular/angioproliferative tumor that most often presents with cutaneous lesions but may involve mucosal surfaces and visceral organs, particularly when host immune function is impaired (e.g., HIV infection or iatrogenic immunosuppression) (russo2024kaposi’ssarcomaevaluation pages 1-2, patel2023clinicalmanagementof pages 2-4). Multiple sources emphasize that HHV-8/KSHV infection is the necessary etiologic agent, with immune dysfunction acting as a key enabling factor for tumorigenesis (denaro2024managementandfuture pages 2-5, denaro2024managementandfuture pages 1-2).

Current clinical-epidemiologic classification: four major subtypes (classic, endemic, iatrogenic, epidemic/HIV-associated) are widely accepted, with a proposed fifth subtype in HIV-negative MSM described in recent reviews (denaro2024managementandfuture pages 1-2, patel2023clinicalmanagementof pages 2-4).

2. Etiology

2.1 Primary causal factor (infectious)

Kaposi sarcoma herpesvirus (KSHV) / human herpesvirus-8 (HHV-8) is the etiologic agent of KS (denaro2024managementandfuture pages 2-5, denaro2024managementandfuture pages 1-2).
In a clinical management review, KSHV is described as a lifelong persistent herpesvirus with two infection programs: latency (default) and lytic replication, infecting multiple cell types (including B cells and endothelial-lineage cells), and with disease manifestations varying by latent vs lytic phenotype (patel2023clinicalmanagementof pages 2-4).

Direct abstract quotes (supporting etiology/definition): - “Kaposi sarcoma (KS) is an intermediate-grade vascular tumour that has undergone major treatment and diagnostic breakthroughs following the discovery of Human herpesvirus 8 (HHV8).” (Bagratee et al., 2025) (bagratee2025recentadvancesin pages 4-6) - “Kaposi’s sarcoma (KS) is a cutaneous neoplasm of endothelial origin. The causative agent is the human herpes virus-8 (HHV-8) which, combined with an immune system impairment, causes cell proliferation.” (Denaro et al., 2024) (denaro2024managementandfuture pages 1-2)

2.2 Risk factors

Immunodeficiency / immune dysregulation - HIV infection and advanced immunosuppression are strongly linked to epidemic KS and to more frequent visceral/mucosal involvement (denaro2024managementandfuture pages 2-5, patel2023clinicalmanagementof pages 2-4). - Iatrogenic immunosuppression (e.g., after solid organ transplantation) is a major risk context; classic KS tends to be more indolent, while iatrogenic KS may improve when immunosuppression is reduced (denaro2024managementandfuture pages 2-5, saowapa2024evaluatingkaposisarcoma pages 1-2).

Transplant / immunosuppression-related risk (quantitative): - One evidence-based review states that transplant recipients have a roughly 60-fold increased risk of iatrogenic KS (denaro2024managementandfuture pages 2-5). - A kidney-transplant meta-analysis estimated KS prevalence 1.5% overall, with higher prevalence in African and Middle Eastern recipients (1.7% each) vs Western recipients (0.07%) and increased odds in males (OR 2.36) (Saowapa et al., 2024; published Jan 2024) (saowapa2024evaluatingkaposisarcoma pages 1-2).

Demographic/geographic risk patterns - Classic KS is described as more frequent in older men and in Mediterranean/Eastern European/Middle Eastern ancestry groups (denaro2024managementandfuture pages 2-5, denaro2024managementandfuture pages 1-2).

2.3 Protective factors

Antiretroviral therapy (ART) for HIV is consistently associated with reduced KS incidence and improved outcomes, interpreted as immune reconstitution and improved HIV control (raja2025kaposisarcomaincidence pages 1-2, akanbi2023incidentkaposisarcoma pages 2-4).

2.4 Gene–environment / host–virus interactions

Mechanistically, KSHV’s latent and lytic programs, host immune impairment, and inflammatory/angiogenic cytokine environments (e.g., IL-6, VEGF) interact to drive angioproliferation and lesion evolution (denaro2024managementandfuture pages 2-5, patel2023clinicalmanagementof pages 2-4).

3. Phenotypes (clinical manifestations)

3.1 Core phenotypes and HPO suggestions

KS lesions are classically described as violaceous/purple macules, papules, plaques, and nodules; transplant-associated and HIV-associated disease may be disseminated and involve mucosal and visceral sites (patel2023clinicalmanagementof pages 2-4, saowapa2024evaluatingkaposisarcoma pages 1-2).

Cutaneous lesions (symptom/sign) - Description: Cutaneous lesions are common and often lower-extremity predominant (russo2024kaposi’ssarcomaevaluation pages 1-2, patel2023clinicalmanagementof pages 2-4). - HPO suggestions: Cutaneous hemangioma/vascular lesion, Skin nodule, Purpura, Hyperpigmented skin lesion (proposed mappings).

Mucosal/oral involvement (clinical sign) - Description: Oral/oropharyngeal disease is recognized in KS, especially in epidemic KS (patel2023clinicalmanagementof pages 2-4). - HPO suggestions: Oral mucosal lesion, Gingival lesion, Palatal lesion (proposed mappings).

Visceral involvement (clinical sign/complication) - GI involvement: KS may involve GI tract; endoscopic biopsy is recommended for suspicious lesions (patel2023clinicalmanagementof pages 2-4). - Pulmonary involvement: Pulmonary/airway KS can occur; bronchoscopy is important but biopsy is often avoided due to bleeding risk (patel2023clinicalmanagementof pages 2-4). - HPO suggestions: Gastrointestinal hemorrhage, Abdominal pain, Dyspnea, Hemoptysis (proposed mappings).

Lymphatic involvement and edema - Lymphedema is noted as part of disseminated disease definitions in trials and is a recognized complication (volkow2023impactofvalganciclovir pages 1-2). - HPO suggestion: Lymphedema.

3.2 Frequency, onset, and progression (with quantitative examples)

In a mixed-subtype retrospective cohort (Padua, Italy; 1993–2022; n=86), cutaneous involvement occurred in 77.9%, and lower-limb involvement in 51.16%; 61.63% had single-site disease (Russo et al., published Feb 2024) (russo2024kaposi’ssarcomaevaluation pages 1-2, russo2024kaposi’ssarcomaevaluation pages 2-4).
Classic KS is described as typically slow-growing with visceral involvement in <10% (denaro2024managementandfuture pages 2-5).

3.3 Quality-of-life impact

Direct QoL instrument results (e.g., EQ-5D/SF-36) were not available in the retrieved evidence set; however, reviews emphasize symptom palliation, edema reduction, and psychological support as important treatment goals (denaro2024managementandfuture pages 1-2).

4. Genetic / Molecular Information

4.1 Causal genes

No germline causal gene was established in the retrieved evidence as determinative for KS; KS is primarily an infection-associated malignancy. Some reviews discuss host genetic associations (e.g., cytokine pathways) but without a definitive single-gene Mendelian etiology in this evidence set (revenko2026classickaposisarcoma pages 1-2).

4.2 Molecular/target annotations (host)

Open Targets highlights disease–target associations including IL6 and TOP2A (the latter consistent with cytotoxic chemotherapy targets), and retinoid receptor family members (RARA/RARB/RARG/RXR) (OpenTargets Search: Kaposi sarcoma). This is association evidence* and should not be interpreted as causal.

5. Environmental Information

5.1 Infectious agent

KSHV/HHV-8 is the relevant infectious agent (denaro2024managementandfuture pages 1-2, patel2023clinicalmanagementof pages 2-4).

5.2 Immunosuppressive exposures

Post-transplant immunosuppression is strongly associated with iatrogenic KS; reduction/withdrawal of immunosuppression is a key management lever and can lead to remissions (saowapa2024evaluatingkaposisarcoma pages 1-2).

6. Mechanism / Pathophysiology

6.1 Causal chain (current model)

KSHV acquisition and persistence: KSHV establishes lifelong infection with a default latent program; virus can enter multiple cell types and persist in latently infected cells (patel2023clinicalmanagementof pages 2-4).
Immune impairment enables tumorigenesis: HIV infection or iatrogenic immunosuppression reduces immune surveillance, enabling expansion of infected cells and pro-angiogenic inflammation (denaro2024managementandfuture pages 2-5, patel2023clinicalmanagementof pages 2-4).
Latent and lytic gene expression promotes angiogenesis/inflammation: Reviews emphasize that both latent and lytic phases contribute to pathogenesis, including cytokine dysregulation and angiogenic signaling (denaro2024managementandfuture pages 2-5, patel2023clinicalmanagementof pages 2-4).
Lesion development with KSHV-infected spindle cells: KS lesions are characterized by spindle cells with endothelial characteristics and aberrant angiogenesis (li2024mappingherpesvirusdrivenimpacts pages 5-9, li2024mappingherpesvirusdrivenimpacts pages 1-5).

6.2 Cell types (CL suggestions)

Endothelial cells (spindle cells with endothelial characteristics) are central (CL: endothelial cell; proposed) (li2024mappingherpesvirusdrivenimpacts pages 5-9, li2024mappingherpesvirusdrivenimpacts pages 1-5).
B cells are a KSHV-infected reservoir/cell type relevant across KSHV diseases (CL: B cell) (patel2023clinicalmanagementof pages 2-4).
Fibroblast-like stromal cells / tumor-associated fibroblast-like cells implicated in xenograft microenvironment and CXCL12 signaling (CL: fibroblast) (li2024mappingherpesvirusdrivenimpacts pages 5-9).

6.3 Pathway/process annotations (GO suggestions)

Evidence-supported processes to map include: - Angiogenesis / blood vessel morphogenesis (GO: angiogenesis, blood vessel development) (denaro2024managementandfuture pages 2-5, li2024mappingherpesvirusdrivenimpacts pages 5-9). - Inflammatory response / cytokine-mediated signaling (e.g., IL-6-related biology) (GO: cytokine-mediated signaling pathway) (denaro2024managementandfuture pages 2-5, patel2023clinicalmanagementof pages 2-4). - Immune evasion and immune system process (GO: immune system process) (patel2023clinicalmanagementof pages 2-4).

6.4 Recent developments (2023–2024 priority)

Patient-derived xenograft (PDX) models and spatial transcriptomics (2024) - A 2024 bioRxiv preprint established orthotopic KS PDX models with high engraftment and demonstrated expansion of LANA+ KSHV-infected endothelial regions and increased viral transcripts by spatial transcriptomics (Li et al., posted Sep 2024) (li2024mappingherpesvirusdrivenimpacts pages 5-9, li2024mappingherpesvirusdrivenimpacts pages 1-5). - Quantitative highlights: KS tumors maintained in 27/28 PDXs up to 272 days; LANA+ cell density increased mean 4.3-fold; LANA+ fraction 15%→62%; dual LANA+/Ki-67+ cells 1%→5.6% (li2024mappingherpesvirusdrivenimpacts pages 5-9).

7. Anatomical Structures Affected

7.1 Organ/tissue involvement (UBERON suggestions)

Skin (UBERON: skin)—primary site in many cases (russo2024kaposi’ssarcomaevaluation pages 1-2).
Lymph node (UBERON: lymph node)—may be involved, including without skin lesions in some contexts (patel2023clinicalmanagementof pages 2-4).
Gastrointestinal tract (UBERON: gastrointestinal tract) (patel2023clinicalmanagementof pages 2-4).
Respiratory system / lung / bronchus (UBERON: lung, bronchus) (patel2023clinicalmanagementof pages 2-4).

7.2 Subcellular and compartments

Not specifically addressed in the retrieved KS-focused evidence; KSHV latency as episomes and latent gene expression are described at a conceptual level (patel2023clinicalmanagementof pages 2-4).

8. Temporal Development

8.1 Onset patterns

Classic KS: typically older age at onset (median ~70 years reported) (denaro2024managementandfuture pages 2-5).
Endemic KS: includes childhood forms (median age 4–9 years in one review summary) (denaro2024managementandfuture pages 2-5).

8.2 Progression and staging

KS can be indolent (classic) or aggressive with visceral and nodal disease (HIV-associated) (denaro2024managementandfuture pages 2-5).
Detailed staging systems for classic KS were not extracted textually here, but the Denaro 2024 review includes staging tables and a systemic therapy management table (image evidence below) (denaro2024managementandfuture media 1e1c9584).

9. Inheritance and Population

9.1 Epidemiology (recent statistics)

United States (registry-based; 1999–2020) - “From 1999 to 2020, 27,886 KS cases and 4,380 deaths occurred.” (Raja et al., published Nov 2025) (raja2025kaposisarcomaincidence pages 1-2). - Sex disparity: “Overall AAIR was 0.99 in men versus 0.10 in women, and AAMR 0.16 versus 0.01” per 100,000 (raja2025kaposisarcomaincidence pages 1-2). - Race disparity: “Black men experienced the highest AAIR (2.23) and AAMR (0.40)… exceeding White men (0.79 and 0.13)” (raja2025kaposisarcomaincidence pages 1-2).

Nigeria (HIV clinic cohort; 2006–2016; ART eligibility expansion) - Overall incident KS: 2.35 per 1,000 person-years (95% CI 2.01–2.74) (Akanbi et al., published Sep 2023) (akanbi2023incidentkaposisarcoma pages 2-4). - Incidence declined from 2.53 to 1.58 per 1,000 PY comparing 2006–2009 vs 2010–2016 (akanbi2023incidentkaposisarcoma pages 2-4). - ART use strongly reduced risk (adjusted HR ~0.17) and male sex increased risk (HR ~1.64) (akanbi2023incidentkaposisarcoma pages 6-7).

9.2 Population demographics

Mixed-subtype cohort (Italy): strong male predominance (89.53%) (russo2024kaposi’ssarcomaevaluation pages 1-2).
Kidney transplant meta-analysis: male predominance (OR 2.36) (saowapa2024evaluatingkaposisarcoma pages 1-2).

10. Diagnostics

10.1 Clinical and pathology diagnosis (gold standards)

Diagnosis relies on biopsy with histopathology and immunohistochemistry (russo2024kaposi’ssarcomaevaluation pages 1-2).
A 2023 clinical management review emphasizes skin biopsy showing spindle cells and KSHV LANA immunohistochemistry positivity as a diagnostic standard; GI lesions should be biopsied during endoscopy, and bronchoscopy is used to evaluate suspected pulmonary KS (biopsy often avoided due to bleeding risk) (patel2023clinicalmanagementof pages 2-4).

10.2 Virologic testing

A contemporary review reports strong performance of LANA IHC and highlights PCR-based detection; it reports that LANA-1 positivity was “100% (50/50) of KS cases being positive and all other non-KS lesions being negative” in one cited series (Bagratee et al., 2025) (bagratee2025recentadvancesin pages 4-6).

10.3 Imaging

FDG-PET/CT can help define extent of disease in some contexts (patel2023clinicalmanagementof pages 2-4).

10.4 Differential diagnosis

KS has histopathologic mimics (e.g., angiosarcoma, hemangioma/vascular lesions, pyogenic granuloma) emphasized in the contemporary diagnostic review (bagratee2025recentadvancesin pages 4-6).

11. Outcomes / Prognosis

11.1 Real-world outcomes (retrospective cohort; 1993–2022)

In the 86-patient cohort, “A persistent response was observed in approximately 65% of patients, with a 22% relapse rate (at least 2 years). The overall survival ranges from 90 to 70% at 2 to 10 years after the diagnosis. Iatrogenic KS demonstrated a higher mortality (52.9%).” (Russo et al., 2024 abstract) (russo2024kaposi’ssarcomaevaluation pages 1-2).

11.2 Early mortality in disseminated HIV-KS with IRIS risk

Severe IRIS-KS is described as high mortality (reported 25–40% in background) and pulmonary involvement is particularly high-risk (volkow2023impactofvalganciclovir pages 1-2).

12. Treatment

12.1 Treatment principles by subtype (current practice)

Epidemic/HIV-associated KS: ART is foundational; systemic therapy and local therapy used per extent, with careful evaluation of visceral disease (patel2023clinicalmanagementof pages 2-4, akanbi2023incidentkaposisarcoma pages 2-4).
Iatrogenic/post-transplant KS: reduction/withdrawal of immunosuppression and regimen modification (e.g., mTOR inhibitor conversion is discussed in transplant-focused literature; within retrieved evidence, immunosuppression reduction is the key described strategy) (saowapa2024evaluatingkaposisarcoma pages 1-2).
Classic KS: local therapy for limited disease; systemic chemotherapy and emerging immunotherapies/targeted strategies for advanced disease; evidence base is more limited than in HIV-KS (denaro2024managementandfuture pages 1-2).

12.2 Systemic chemotherapy

Reviews summarize cytotoxic regimens (anthracyclines, vinca alkaloids, paclitaxel), with reported response rates often in the 70–90% range but frequently transient in classic KS (denaro2024managementandfuture pages 2-5).

12.3 Antiviral/virus-targeted strategies (recent clinical trial evidence)

Valganciclovir in disseminated KS to mitigate severe IRIS-KS (PLOS ONE, May 2023) - Trial design: valganciclovir 900 mg BID for four weeks before cART and continued to week 48 vs cART initiation alone (volkow2023impactofvalganciclovir pages 1-2). - Key outcomes (direct abstract numbers): severe-IRIS-KS attributable mortality 0/20 vs 3/20 (p=0.09); pulmonary KS mortality 0/5 vs 3/4 (P=0.048); among survivors at week 48, 82% achieved >80% remission (volkow2023impactofvalganciclovir pages 1-2).

12.4 Repurposed/adjunct antiretroviral class drugs in classic KS (phase II, 2024)

Indinavir + chemotherapy strategy in advanced classic KS (Cancer Research Communications; Aug 2024): 22/22 evaluable patients responded to debulking chemotherapy; 16 entered indinavir maintenance; overall response rate 75% with estimated median response duration 43 months (sgadari2024clinicalefficacyof pages 1-2).

12.5 Post-transplant KS management outcomes (meta-analysis)

In kidney transplant recipients, reduction/withdrawal of immunosuppression alone resulted in 47.8% complete remissions across included studies (Saowapa et al., Jan 2024) (saowapa2024evaluatingkaposisarcoma pages 1-2).

12.6 Immunotherapy and emerging strategies

Contemporary expert review notes “new therapies… focus on chemotherapy-sparing options that seek to target the underlying viral pathogenesis or immunotherapy strategies” (Patel et al., 2023) (patel2023clinicalmanagementof pages 2-4).
Clinical trials registered on ClinicalTrials.gov in the current tool state include checkpoint inhibitor strategies (e.g., intralesional nivolumab NCT03316274; pembrolizumab phase II in classic/endemic KS NCT03469804; etc.), but trial outcomes were not retrieved here because only trial registry metadata (not results) were available.

12.7 Treatment ontology (MAXO suggestions)

Antiretroviral therapy (MAXO: antiretroviral therapy; proposed) (akanbi2023incidentkaposisarcoma pages 2-4).
Reduction/withdrawal of immunosuppression (MAXO: immunosuppressive therapy adjustment) (saowapa2024evaluatingkaposisarcoma pages 1-2).
Systemic chemotherapy (MAXO: chemotherapy) (denaro2024managementandfuture pages 2-5).
Antiviral therapy (valganciclovir) (MAXO: antiviral therapy) (volkow2023impactofvalganciclovir pages 1-2).

12.8 Treatment algorithm (visual evidence)

The Denaro 2024 evidence-based review includes a systemic therapy management table (Table 6), serving as a practical algorithm for systemic treatment lines/dosing in classic KS.

(denaro2024managementandfuture media 1e1c9584)

13. Prevention

13.1 Primary prevention

No licensed KSHV vaccine is referenced in the retrieved evidence.

13.2 Secondary prevention (early HIV diagnosis and ART initiation)

In Nigeria, ART eligibility expansion was associated with reduced incident KS, likely through earlier care/ART initiation (akanbi2023incidentkaposisarcoma pages 1-2, akanbi2023incidentkaposisarcoma pages 2-4).
A US registry analysis contextualizes ART introduction (1996) with subsequent declines in KS incidence and improved survival, while noting persistent disparities (raja2025kaposisarcomaincidence pages 1-2).

13.3 Tertiary prevention (preventing complications/relapse)

In transplant-associated KS, balancing immunosuppression reduction with graft function is emphasized, with immunosuppression reduction producing remissions in many cases (saowapa2024evaluatingkaposisarcoma pages 1-2).

14. Other Species / Natural Disease

No veterinary/natural disease evidence was retrieved in the current tool context; this section is therefore not populated from evidence and should be revisited with targeted veterinary literature searches.

15. Model Organisms

15.1 Patient-derived xenografts (2024)

A 2024 KS PDX platform supports mechanistic and therapeutic investigations, including spatial transcriptomics readouts and tumor microenvironment signaling (e.g., CXCL12→CXCR4) (li2024mappingherpesvirusdrivenimpacts pages 5-9, li2024mappingherpesvirusdrivenimpacts pages 1-5).
This addresses a known limitation: rapid loss of KSHV infection when KS tumor cells are explanted into culture (li2024mappingherpesvirusdrivenimpacts pages 1-5).

Consolidated subtype and statistics summary

Subtype	Etiology/context	Common sites	Key quantitative notes	Key citations
Classic KS	HHV-8/KSHV-associated; typically older men of Mediterranean/Jewish origin; generally indolent	Predominantly lower extremity skin; GI tract and lung are the most common metastatic/visceral sites when present	Median age ~70 years; visceral involvement reported in <10%; systemic chemotherapy responses often 70–90% but usually transient (denaro2024managementandfuture pages 2-5, denaro2024managementandfuture pages 1-2)	(denaro2024managementandfuture pages 2-5, denaro2024managementandfuture pages 1-2)
Epidemic/HIV-associated KS	HHV-8/KSHV plus HIV-related immunosuppression; more aggressive than classic KS	Skin, mucosa, lymph nodes, GI tract, respiratory tract	Historical 5-year OS about 12% pre-ART; with effective ART, survival improved to 68–95% (denaro2024managementandfuture pages 2-5). In a Nigerian HIV cohort, incidence declined from 2.53 to 1.58 per 1,000 person-years after ART eligibility expansion; ART use associated with markedly lower KS risk (adjusted HR ~0.17), while male sex increased risk (HR ~1.64) (akanbi2023incidentkaposisarcoma pages 6-7, akanbi2023incidentkaposisarcoma pages 2-4)	(denaro2024managementandfuture pages 2-5, akanbi2023incidentkaposisarcoma pages 6-7, akanbi2023incidentkaposisarcoma pages 2-4)
Endemic/African KS	HHV-8/KSHV in sub-Saharan Africa; affects adults and children; pediatric disease can be aggressive/lymphadenopathic	Skin, lymph nodes; may have visceral disease; pediatric nodal disease notable	Childhood median age reported 4–9 years; some series/reviews report aggressive exophytic disease with bony invasion 31% and lymphedema 17% (denaro2024managementandfuture pages 2-5, bagratee2025recentadvancesin pages 4-6)	(denaro2024managementandfuture pages 2-5, bagratee2025recentadvancesin pages 4-6)
Iatrogenic/transplant-associated KS	HHV-8/KSHV with prolonged immunosuppression, especially after solid-organ transplantation or corticosteroid exposure	Cutaneous lesions common; visceral and nodal involvement may occur, sometimes without skin lesions	Transplant recipients have about 60-fold increased risk of KS (denaro2024managementandfuture pages 2-5). Kidney transplant meta-analysis: pooled prevalence 1.5% overall; 1.7% in African and Middle Eastern recipients vs 0.07% in Western recipients; male predominance OR 2.36; cyclosporine-based immunosuppression in 79.6% of KS cases; reduction/withdrawal of immunosuppression alone achieved 47.8% complete remissions (saowapa2024evaluatingkaposisarcoma pages 1-2). In a retrospective cohort, iatrogenic KS mortality reached 52.9% (russo2024kaposi’ssarcomaevaluation pages 1-2)	(denaro2024managementandfuture pages 2-5, russo2024kaposi’ssarcomaevaluation pages 1-2, saowapa2024evaluatingkaposisarcoma pages 1-2)
HIV-negative MSM-associated KS	Proposed fifth subtype; HHV-8/KSHV without HIV infection; usually milder than epidemic KS	Often localized cutaneous and/or mucosal disease	Recognized as a distinct but less well-characterized subtype in recent reviews; robust epidemiologic estimates remain limited (denaro2024managementandfuture pages 2-5, patel2023clinicalmanagementof pages 2-4)	(denaro2024managementandfuture pages 2-5, patel2023clinicalmanagementof pages 2-4)
KS overall clinical presentation	Angioproliferative/vascular endothelial tumor driven by HHV-8/KSHV, often requiring immunosuppression or immune dysregulation as cofactor	Skin most common; oral cavity/mucosa, lymph nodes, GI tract, lungs/airways also involved	In a single-center cohort of 86 KS patients, 89.53% were male, 43.02% had classic KS, and 77.9% had cutaneous involvement; 61.63% had single-site disease and 51.16% had lower-limb involvement (russo2024kaposi’ssarcomaevaluation pages 1-2, russo2024kaposi’ssarcomaevaluation pages 2-4)	(russo2024kaposi’ssarcomaevaluation pages 1-2, russo2024kaposi’ssarcomaevaluation pages 2-4)
Real-world outcomes across mixed KS cohort	Multidisciplinary management using surgery, ART, chemotherapy, radiotherapy, or combinations	Depends on subtype and extent; skin predominant overall	In the 86-patient cohort, persistent response occurred in about 65%, relapse in 22% (≥2 years), and overall survival ranged from 90% to 70% at 2 to 10 years after diagnosis (russo2024kaposi’ssarcomaevaluation pages 1-2)	(russo2024kaposi’ssarcomaevaluation pages 1-2)
United States epidemiology (all KS)	Population-level burden reflects ART-era declines but persistent disparities	Not site-specific; registry analysis of all KS	From 1999–2020, there were 27,886 KS cases and 4,380 deaths. Overall AAIR: 0.99 in men vs 0.10 in women; AAMR: 0.16 vs 0.01. Black men had the highest AAIR/AAMR (2.23/0.40) vs White men (0.79/0.13). Incidence declined 46.7% in men and 58.9% in women; male mortality declined 66.4% (raja2025kaposisarcomaincidence pages 1-2)	(raja2025kaposisarcomaincidence pages 1-2)
Disseminated HIV-KS with IRIS risk	Advanced HIV-associated KS starting cART; high HHV-8 viral load linked to severe IRIS-KS	Disseminated disease defined by pulmonary, lymph-node, GI involvement, lymphedema, or ≥30 skin lesions	In an RCT of valganciclovir before/with cART, severe-IRIS-KS attributable mortality was 0/20 vs 3/20 in controls; in pulmonary KS, mortality was 0/5 vs 3/4; among survivors at week 48, 82% achieved >80% remission (volkow2023impactofvalganciclovir pages 1-2)	(volkow2023impactofvalganciclovir pages 1-2)
Advanced classic KS trial	Elderly patients with progressive/advanced classic KS treated with debulking chemotherapy followed by indinavir maintenance	Primarily cutaneous disease burden requiring systemic control	In a phase II trial, 22/22 evaluable patients responded to debulking chemotherapy; 16 entered indinavir maintenance; overall response rate at end of maintenance was 75% with estimated median response duration 43 months (sgadari2024clinicalefficacyof pages 1-2)	(sgadari2024clinicalefficacyof pages 1-2)
Experimental model systems (KS PDX)	Patient-derived xenografts from cutaneous KS biopsies in immunodeficient mice; useful for mechanistic and translational studies	Orthotopic cutaneous KS xenografts retaining infected endothelial/spindle-cell populations	Tumors were maintained in 27/28 PDXs (up to 272 days); LANA+ endothelial cell density increased a mean 4.3-fold; LANA+ cells increased from 15% to 62%; dual LANA+/Ki-67+ cells increased from 1% to 5.6% (li2024mappingherpesvirusdrivenimpacts pages 5-9, li2024mappingherpesvirusdrivenimpacts pages 1-5)	(li2024mappingherpesvirusdrivenimpacts pages 5-9, li2024mappingherpesvirusdrivenimpacts pages 1-5)

Table: This table summarizes Kaposi sarcoma subtypes, risk contexts, anatomic patterns, and key quantitative epidemiology, treatment, and model-system findings extracted from the gathered evidence. It is useful as a compact evidence map for subtype-specific disease characterization and recent outcome statistics.

Key “expert opinion” perspectives (authoritative reviews)

KS and other KSHV-associated diseases are “often underdiagnosed… in the United States and worldwide,” and emerging therapies aim to target viral pathogenesis or employ immunotherapy approaches (Patel et al., 2023, Expert Review of Anti-infective Therapy) (patel2023clinicalmanagementof pages 2-4).
For classic KS specifically, Denaro et al. (2024) emphasize limited high-quality evidence and the importance of multidisciplinary referral centers and clinical trial enrollment (denaro2024managementandfuture pages 1-2).

Evidence limitations and gaps (for knowledge base completion)

This tool run did not retrieve MeSH, Orphanet, OMIM, or a definitive MONDO ID for Kaposi sarcoma (as distinct from “susceptibility to”), nor did it retrieve a standardized list of HPO terms with validated frequencies.
Checkpoint inhibitor efficacy in KS was not populated with outcome data here because results papers were not retrieved (only trial registry entries).
Additional targeted searches (e.g., NCCN guideline text, WHO/ICD-11, MeSH Browser, MONDO release files, and key KS immunotherapy trial publications) would be needed for a fully populated ontology-first knowledge base entry.

References

(russo2024kaposi’ssarcomaevaluation pages 1-2): Irene Russo, Dario Marino, Claudia Cozzolino, Paolo Del Fiore, Fitnete Nerjaku, Silvia Finotto, Annamaria Cattelan, Maria Luisa Calabrò, Anna Belloni Fortina, Francesco Russano, Marcodomenico Mazza, Sara Galuppo, Elisabetta Bezzon, Marta Sbaraglia, Marco Krengli, Antonella Brunello, Simone Mocellin, Stefano Piaserico, and Mauro Alaibac. Kaposi’s sarcoma: evaluation of clinical features, treatment outcomes, and prognosis in a single-center retrospective case series. Cancers, 16:691, Feb 2024. URL: https://doi.org/10.3390/cancers16040691, doi:10.3390/cancers16040691. This article has 19 citations.
(denaro2024managementandfuture pages 1-2): Nerina Denaro, Alice Indini, Lucia Brambilla, Angelo Valerio Marzano, Ornella Garrone, and Athanasia Tourlaki. Management and future therapeutic perspectives of classic kaposi’s sarcoma: an evidence-based review. OncoTargets and Therapy, 17:961-976, Nov 2024. URL: https://doi.org/10.2147/ott.s468787, doi:10.2147/ott.s468787. This article has 8 citations.
(raja2025kaposisarcomaincidence pages 1-2): Ahsan Raza Raja, Philippos Apolinario Costa, and Muhammad Hyder Junejo. Kaposi sarcoma incidence and mortality trends and disparities in the united states. Infectious Agents and Cancer, Nov 2025. URL: https://doi.org/10.1186/s13027-025-00710-x, doi:10.1186/s13027-025-00710-x. This article has 1 citations and is from a peer-reviewed journal.
(OpenTargets Search: Kaposi sarcoma): Open Targets Query (Kaposi sarcoma, 11 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(patel2023clinicalmanagementof pages 2-4): Roshani Patel, Kathryn Lurain, Robert Yarchoan, and Ramya Ramaswami. Clinical management of kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies. Expert Review of Anti-infective Therapy, 21:929-941, Aug 2023. URL: https://doi.org/10.1080/14787210.2023.2247161, doi:10.1080/14787210.2023.2247161. This article has 38 citations and is from a peer-reviewed journal.
(volkow2023impactofvalganciclovir pages 1-2): Patricia Volkow, Leslie Chavez Galan, Lucero Ramon-Luing, Judith Cruz-Velazquez, Patricia Cornejo-Juarez, Isabel Sada-Ovalle, Rogelio Perez-Padilla, and Beda Islas-Muñoz. Impact of valganciclovir therapy on severe iris-kaposi sarcoma mortality: an open-label, parallel, randomized controlled trial. PLOS ONE, 18:e0280209, May 2023. URL: https://doi.org/10.1371/journal.pone.0280209, doi:10.1371/journal.pone.0280209. This article has 11 citations and is from a peer-reviewed journal.
(akanbi2023incidentkaposisarcoma pages 2-4): Maxwell. O. Akanbi, Lucy. A. Bilaver, Chad Achenbach, Lisa. R. Hirschhorn, Adovich. S. Rivera, Orimisan. S. Adekolujo, Kehinde. U. A. Adekola, Olugbenga. A. Silas, Patricia. A. Agaba, Oche Agbaji, Nathan. Y. Shehu, Solomon. A. Sagay, Lifang Hou, and Robert. L. Murphy. Incident kaposi sarcoma during the expansion of antiretroviral therapy eligibility in nigeria: a retrospective cohort study. BMC Cancer, Sep 2023. URL: https://doi.org/10.1186/s12885-023-11402-3, doi:10.1186/s12885-023-11402-3. This article has 3 citations and is from a peer-reviewed journal.
(denaro2024managementandfuture pages 2-5): Nerina Denaro, Alice Indini, Lucia Brambilla, Angelo Valerio Marzano, Ornella Garrone, and Athanasia Tourlaki. Management and future therapeutic perspectives of classic kaposi’s sarcoma: an evidence-based review. OncoTargets and Therapy, 17:961-976, Nov 2024. URL: https://doi.org/10.2147/ott.s468787, doi:10.2147/ott.s468787. This article has 8 citations.
(bagratee2025recentadvancesin pages 4-6): Tayarv Jayd Bagratee, Veron Ramsuran, Mpumelelo Msimang, and Pratistadevi Kanaye Ramdial. Recent advances in the histopathology, molecular biology, and treatment of kaposi sarcoma: a contemporary review. International Journal of Molecular Sciences, 26:10058, Oct 2025. URL: https://doi.org/10.3390/ijms262010058, doi:10.3390/ijms262010058. This article has 2 citations.
(saowapa2024evaluatingkaposisarcoma pages 1-2): Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Chalothorn Wannaphut, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, and Pakin Lalitnithi. Evaluating kaposi sarcoma in kidney transplant patients: a systematic review and meta-analysis. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52527, doi:10.7759/cureus.52527. This article has 20 citations.
(russo2024kaposi’ssarcomaevaluation pages 2-4): Irene Russo, Dario Marino, Claudia Cozzolino, Paolo Del Fiore, Fitnete Nerjaku, Silvia Finotto, Annamaria Cattelan, Maria Luisa Calabrò, Anna Belloni Fortina, Francesco Russano, Marcodomenico Mazza, Sara Galuppo, Elisabetta Bezzon, Marta Sbaraglia, Marco Krengli, Antonella Brunello, Simone Mocellin, Stefano Piaserico, and Mauro Alaibac. Kaposi’s sarcoma: evaluation of clinical features, treatment outcomes, and prognosis in a single-center retrospective case series. Cancers, 16:691, Feb 2024. URL: https://doi.org/10.3390/cancers16040691, doi:10.3390/cancers16040691. This article has 19 citations.
(revenko2026classickaposisarcoma pages 1-2): Daniela Revenko, Natali Shirron, Reut Shainer, Emily Avitan-Hersh, and Alona Zer. Classic kaposi sarcoma: current treatment strategies and emerging therapeutic approaches. Cancers, 18:1008, Mar 2026. URL: https://doi.org/10.3390/cancers18061008, doi:10.3390/cancers18061008. This article has 0 citations.
(li2024mappingherpesvirusdrivenimpacts pages 5-9): Xiaofan Li, Zoë Weaver Ohler, Amanda Day, Laura Bassel, Anna Grosskopf, Bahman Afsari, Takanobu Tagawa, Wendi Custer, Ralph Mangusan, Kathryn Lurain, Robert Yarchoan, Joseph Ziegelbauer, Ramya Ramaswami, and Laurie T. Krug. Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of kaposi sarcoma in patient-derived mouse models. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615429, doi:10.1101/2024.09.27.615429. This article has 5 citations.
(li2024mappingherpesvirusdrivenimpacts pages 1-5): Xiaofan Li, Zoë Weaver Ohler, Amanda Day, Laura Bassel, Anna Grosskopf, Bahman Afsari, Takanobu Tagawa, Wendi Custer, Ralph Mangusan, Kathryn Lurain, Robert Yarchoan, Joseph Ziegelbauer, Ramya Ramaswami, and Laurie T. Krug. Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of kaposi sarcoma in patient-derived mouse models. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615429, doi:10.1101/2024.09.27.615429. This article has 5 citations.
(denaro2024managementandfuture media 1e1c9584): Nerina Denaro, Alice Indini, Lucia Brambilla, Angelo Valerio Marzano, Ornella Garrone, and Athanasia Tourlaki. Management and future therapeutic perspectives of classic kaposi’s sarcoma: an evidence-based review. OncoTargets and Therapy, 17:961-976, Nov 2024. URL: https://doi.org/10.2147/ott.s468787, doi:10.2147/ott.s468787. This article has 8 citations.
(akanbi2023incidentkaposisarcoma pages 6-7): Maxwell. O. Akanbi, Lucy. A. Bilaver, Chad Achenbach, Lisa. R. Hirschhorn, Adovich. S. Rivera, Orimisan. S. Adekolujo, Kehinde. U. A. Adekola, Olugbenga. A. Silas, Patricia. A. Agaba, Oche Agbaji, Nathan. Y. Shehu, Solomon. A. Sagay, Lifang Hou, and Robert. L. Murphy. Incident kaposi sarcoma during the expansion of antiretroviral therapy eligibility in nigeria: a retrospective cohort study. BMC Cancer, Sep 2023. URL: https://doi.org/10.1186/s12885-023-11402-3, doi:10.1186/s12885-023-11402-3. This article has 3 citations and is from a peer-reviewed journal.
(sgadari2024clinicalefficacyof pages 1-2): Cecilia Sgadari, Biancamaria Scoppio, Orietta Picconi, Antonella Tripiciano, Francesca Maria Gaiani, Vittorio Francavilla, Angela Arancio, Massimo Campagna, Clelia Palladino, Sonia Moretti, Paolo Monini, Lucia Brambilla, and Barbara Ensoli. Clinical efficacy of the hiv protease inhibitor indinavir in combination with chemotherapy for advanced classic kaposi sarcoma treatment: a single-arm, phase ii trial in the elderly. Cancer Research Communications, 4:2112-2122, Aug 2024. URL: https://doi.org/10.1158/2767-9764.crc-24-0102, doi:10.1158/2767-9764.crc-24-0102. This article has 5 citations and is from a peer-reviewed journal.
(akanbi2023incidentkaposisarcoma pages 1-2): Maxwell. O. Akanbi, Lucy. A. Bilaver, Chad Achenbach, Lisa. R. Hirschhorn, Adovich. S. Rivera, Orimisan. S. Adekolujo, Kehinde. U. A. Adekola, Olugbenga. A. Silas, Patricia. A. Agaba, Oche Agbaji, Nathan. Y. Shehu, Solomon. A. Sagay, Lifang Hou, and Robert. L. Murphy. Incident kaposi sarcoma during the expansion of antiretroviral therapy eligibility in nigeria: a retrospective cohort study. BMC Cancer, Sep 2023. URL: https://doi.org/10.1186/s12885-023-11402-3, doi:10.1186/s12885-023-11402-3. This article has 3 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Kaposi Sarcoma (KS): Disease Characteristics Research Report

Target Disease

Synonyms / alternative names

Evidence provenance

1. Disease Information (overview and current understanding)

2. Etiology

2.1 Primary causal factor (infectious)

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment / host–virus interactions

3. Phenotypes (clinical manifestations)

3.1 Core phenotypes and HPO suggestions

3.2 Frequency, onset, and progression (with quantitative examples)

3.3 Quality-of-life impact

4. Genetic / Molecular Information

4.1 Causal genes

4.2 Molecular/target annotations (host)

5. Environmental Information

5.1 Infectious agent

5.2 Immunosuppressive exposures

6. Mechanism / Pathophysiology

6.1 Causal chain (current model)

6.2 Cell types (CL suggestions)

6.3 Pathway/process annotations (GO suggestions)

6.4 Recent developments (2023–2024 priority)

7. Anatomical Structures Affected

7.1 Organ/tissue involvement (UBERON suggestions)

7.2 Subcellular and compartments

8. Temporal Development

8.1 Onset patterns

8.2 Progression and staging

9. Inheritance and Population

9.1 Epidemiology (recent statistics)

9.2 Population demographics

10. Diagnostics

10.1 Clinical and pathology diagnosis (gold standards)

10.2 Virologic testing

10.3 Imaging

10.4 Differential diagnosis

11. Outcomes / Prognosis

11.1 Real-world outcomes (retrospective cohort; 1993–2022)

11.2 Early mortality in disseminated HIV-KS with IRIS risk

12. Treatment

12.1 Treatment principles by subtype (current practice)

12.2 Systemic chemotherapy

12.3 Antiviral/virus-targeted strategies (recent clinical trial evidence)

12.4 Repurposed/adjunct antiretroviral class drugs in classic KS (phase II, 2024)

12.5 Post-transplant KS management outcomes (meta-analysis)

12.6 Immunotherapy and emerging strategies

12.7 Treatment ontology (MAXO suggestions)

12.8 Treatment algorithm (visual evidence)

13. Prevention

13.1 Primary prevention

13.2 Secondary prevention (early HIV diagnosis and ART initiation)

13.3 Tertiary prevention (preventing complications/relapse)

14. Other Species / Natural Disease

15. Model Organisms

15.1 Patient-derived xenografts (2024)

Consolidated subtype and statistics summary

Key “expert opinion” perspectives (authoritative reviews)

Evidence limitations and gaps (for knowledge base completion)